ABSTRACT
BACKGROUND: high recurrence rates of up to 75% within 2 years in pancreatic ductal adenocarcinoma (PDAC) patients resected for cure indicate a high medical need for clinical prediction tools and patient specific treatment approaches. Addition of the EGFR inhibitor erlotinib to adjuvant chemotherapy failed to improve outcome but its efficacy in some patients warrants predictors of responsiveness. PATIENTS AND METHODS: we analysed tumour samples from 293 R0-resected patients from the randomized, multicentre phase III CONKO-005 trial (gemcitabine ± erlotinib) with targeted sequencing, copy number, and RNA expression analyses. FINDINGS: a total of 1086 mutations and 4157 copy-number aberrations (CNAs) with a mean of 17.9 /tumour were identified. Main pathways affected by genetic aberrations were the MAPK-pathway (99%), cell cycle control (92%), TGFß signalling (77%), chromatin remodelling (71%), and the PI3K/AKT pathway (65%). Based on genetic signatures extracted with non-negative matrix factorization we could define five patient clusters, which differed in mutation patterns, gene expression profiles, and survival. In multivariable Cox regression analysis, SMAD4 aberrations were identified as a negative prognostic marker in the gemcitabine arm, an effect that was counteracted when treated with erlotinib (DFS: HR=1.59, p = 0.016, and OS: HR = 1.67, p = 0.014). Integration of differential gene expression analysis established SMAD4 alterations with low MAPK9 expression (n = 91) as a predictive biomarker for longer DFS (HR=0.49; test for interaction, p = 0.02) and OS (HR = 0.32; test for interaction, p = 0.001). INTERPRETATION: this study identified five biologically distinct patient clusters with different actionable lesions and unravelled a previously unappreciated association of SMAD4 alteration status with erlotinib effectiveness. Confirmatory studies and mechanistic experiments are warranted to challenge the hypothesis that SMAD4 status might guide addition of erlotinib treatment in early-stage PDAC patients.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Gene Expression Regulation, Neoplastic/drug effects , Pancreatic Neoplasms/drug therapy , Pancreatic Neoplasms/genetics , Adult , Aged , Aged, 80 and over , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Biomarkers, Tumor , DNA Copy Number Variations , Deoxycytidine/administration & dosage , Deoxycytidine/analogs & derivatives , Erlotinib Hydrochloride/administration & dosage , Female , Humans , Male , Middle Aged , Molecular Targeted Therapy , Mutation , Neoplasm Staging , Pancreatic Neoplasms/metabolism , Pancreatic Neoplasms/pathology , Polymorphism, Single Nucleotide , Prognosis , Proportional Hazards Models , Signal Transduction , Treatment Outcome , Young Adult , GemcitabineABSTRACT
Relapse management is a crucial component of multiple sclerosis care. Acute relapses are defined as new neurological symptoms or worsening of existing symptoms persisting for >24 h that are not attributable to heat, overexertion, or infection. The most commonly used treatment for multiple sclerosis relapse is a 3-5-day course of corticosteroids, primarily intravenous methylprednisolone with or without oral steroid taper. Repository corticotropin injection is also the US FDA-approved option for managing acute relapse, particularly in the patients with inadequate response, intolerability or allergy to corticosteroid treatment; poor venous access; or limited ability to receive home or clinic infusions.
Subject(s)
Adrenocorticotropic Hormone/analogs & derivatives , Adrenocorticotropic Hormone/administration & dosage , Immunologic Factors/administration & dosage , Multiple Sclerosis/drug therapy , Adrenocorticotropic Hormone/adverse effects , Adrenocorticotropic Hormone/pharmacokinetics , Humans , Immunologic Factors/adverse effects , Immunologic Factors/pharmacokinetics , Immunologic Factors/pharmacology , InjectionsSubject(s)
Fluorides/administration & dosage , Adolescent , Child , DMF Index , Female , Follow-Up Studies , Humans , Male , Oral Hygiene Index , Periodontal Index , Switzerland , Tablets , Tooth Mobility , Urban PopulationABSTRACT
The Association of Biomedical Communications Directors (ABCD) has recently completed the fifth in its series of surveys of biomedical communications units. The fourth survey, published in 1975, reported staffing patterns, salary data, degrees held, and a variety of other information from units directed by members of the ABCD in the United States and Canada. The current report covers similar data from the 1977-78 academic year and in addition includes information from units whose directors were not members of ABCD but who wished to cooperate in the survey.